XACIATO
Details
- Status
- Prescription
- First Approved
- 2021-12-07
- Routes
- VAGINAL
- Dosage Forms
- GEL
XACIATO Approval History
What XACIATO Treats
1 indicationsXACIATO is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Bacterial Vaginosis
Drugs Similar to XACIATO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
XACIATO FDA Label Details
ProIndications & Usage
FDA Label (PDF)XACIATO is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. 1.1 Bacterial Vaginosis XACIATO ยฎ is indicated for the treatment of bacterial vaginosis in females 12 years and older [see Use in Specific Populations and Clinical Studies ] .
XACIATO Patents & Exclusivity
Patents (2 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.